9.005
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$8.90
Offen:
$8.9
24-Stunden-Volumen:
1.96M
Relative Volume:
0.15
Marktkapitalisierung:
$10.57B
Einnahmen:
$14.33B
Nettoeinkommen (Verlust:
$-3.79B
KGV:
-2.8407
EPS:
-3.17
Netto-Cashflow:
$1.84B
1W Leistung:
+0.96%
1M Leistung:
+1.64%
6M Leistung:
-19.07%
1J Leistung:
-22.75%
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Vergleichen Sie VTRS mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
VTRS
Viatris Inc
|
9.005 | 10.73B | 14.33B | -3.79B | 1.84B | -3.17 |
![]()
ZTS
Zoetis Inc
|
149.09 | 69.30B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.51 | 47.50B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.585 | 44.47B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.16 | 18.83B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
296.61 | 13.43B | 2.99B | 1.21B | 1.13B | 25.06 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-06 | Eingeleitet | Goldman | Neutral |
2024-07-19 | Fortgesetzt | Jefferies | Buy |
2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
2022-11-10 | Hochstufung | UBS | Sell → Neutral |
2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
2022-10-21 | Fortgesetzt | Jefferies | Hold |
2022-06-14 | Eingeleitet | UBS | Sell |
2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
2021-06-15 | Eingeleitet | Citigroup | Neutral |
2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
2021-01-05 | Eingeleitet | Argus | Hold |
2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
What analysts say about Viatris Inc. stockExplosive capital appreciation - jammulinksnews.com
What drives Viatris Inc. stock priceFree Trend-Following Techniques - jammulinksnews.com
Agree To Buy Viatris At $5, Earn 3% Using Options - Nasdaq
VTRS Down on Late-Stage Study Failure of Eye Disease Drug - TradingView
Viatris’ blepharitis ointment fails Phase III trial - Yahoo Finance
Viatris Phase III MR-139 trial in blepharitis misses goal - The Pharma Letter
Viatris Inc. Stock Analysis and ForecastHigh-profit stock alerts - jammulinksnews.com
Is Viatris Inc. a good long term investmentGame-changing capital returns - PrintWeekIndia
Viatris' Setback in Blepharitis Trial: A Harbinger or a Hurdle for Ophthalmic Innovation? - AInvest
Trend Tracker for (VTRS) - news.stocktradersdaily.com
Viatris Inc. Stock Forecasts: Trial Miss Pressures Recovery of Core Business - AInvest
Viatris Stock Slides After Phase 3 Blepharitis Drug Trial Misses Key Target - TradingView
Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review - Benzinga
Why Viatris (VTRS) Stock Is Falling Today - Yahoo Finance
Viatris stock unchanged as Goldman maintains Neutral rating on trial miss - Investing.com
Johnson Fistel, PLLP Investigates Claims on Behalf of - GlobeNewswire
Viatris Stock Tumbles as Eyelid Inflammation Treatment Misses Target - Barron's
Viatris' Resilience in Ophthalmology: Navigating Setbacks and Strategic Growth - AInvest
Why Is Viatris Stock Falling In Pre-market? - Nasdaq
Viatris stock down on late-stage trial setback (VTRS:NASDAQ) - Seeking Alpha
Viatris eye ointment fails late-stage study for eye condition, shares fall - TradingView
Viatris stock falls after Phase 3 blepharitis study misses endpoint - Investing.com
Viatris blepharitis treatment fails to meet primary endpoint in trial - Investing.com Australia
Viatris eye therapy fails to meet late-stage trial goal - TradingView
Viatris Provides Update on Phase 3 Study of MR-139 for Blepharitis - PR Newswire
Viatris (VTRS) Announces Positive Top-line Results from VEGA-3 - MSN
Hypopituitarism Treatment Market Expansion Supported - openPR.com
Viatris: A Contrarian Bet with Minimal Downside Risk - AInvest
Viatris: A Contrarian Bet With Virtually No Downside (NASDAQ:VTRS) - Seeking Alpha
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks - Yahoo Finance
Goldman Sachs Reiterates a Hold Rating on Viatris (VTRS) With a $10 PT - MSN
Viatris Gains China Approval for COPD Drug Yupelri, Triggers $7.5M Payment to Theravance BioPharma - Insider Monkey
Viatris' Canadian Workplace Excellence Fuels Long-Term Resilience in Pharma's Turbulent Landscape - AInvest
Viatris Certified as a Great Place to Work® in Canada - Yahoo Finance
What makes Viatris Inc. stock price move sharplyFree Premium Stock Market Reports - beatles.ru
Non-Opioid Patch Market CAGR 6.6 percent overview and leading - openPR.com
Viatris Inc. (VTRS) Stock Analysis: Evaluating a 24.86% Potential Upside Amidst Financial Headwinds - DirectorsTalk Interviews
J&J wins appeals court ruling against Teva and Viatris in patent dispute over neuro drug - Seeking Alpha
When (VTRS) Moves Investors should Listen - news.stocktradersdaily.com
Viatris sees positive top-line phase 3 results for night driving impairment asset - MSN
J&J defeats generic drugmakers in US appeal over schizophrenia treatment - TradingView
J&J Invega Sustenna Patent Beats Teva, Viatris Appeals (Correct) - Bloomberg Law News
Viatris Inc. (VTRS) Stock Analysis: Exploring a 22.18% Potential Upside Amidst Strong Free Cash Flow and High Dividend Yield - DirectorsTalk Interviews
Theravance higher as China approves Viatris-partnered COPD therapy - MSN
Viatris says second phase 3 trial of blurred vision drug meets goal - Seeking Alpha
Breakthrough in Presbyopia Treatment: Viatris Phase 3 Trial Shows Powerful Vision Improvement Results - Stock Titan
Is Viatris Stock Underperforming the S&P 500? - MSN
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):